



**Initial Experience of a Large, Self-Expanding and Fully
Recapturable Transcatheter Aortic Valve: The UK & Ireland
Implanters' Registry**

Journal:	<i>Catheterization and Cardiovascular Interventions</i>
Manuscript ID	CCI-18-1078.R1
Wiley - Manuscript type:	Original Studies
Keywords:	TVI - Transcatheter Valve Implantation, AVD - Aortic Valve Disease, AVDP - Aortic Valve Disease, Percutaneous Intervention

SCHOLARONE™
Manuscripts

View Only

Initial Experience of a Large, Self-Expanding and Fully Recapturable Transcatheter Aortic Valve: The UK & Ireland Implanters' Registry

Short Title: Initial Experience of a Large TAV

Authors' Names and Academic Degrees: Cameron Dowling, MBBS,^a Sami Firoozi, MBBS (Hons), FRCP^a Niamh Doyle, BSc (Hons),^a Daniel J. Blackman, MD,^b Christopher J. Malkin, MD, MRCP^b Michael S. Cunnington, MD,^b Smriti Saraf, MD,^{b,c} Mamta H. Buch, MB ChB, PhD,^c Richard Levy, MD,^c Saqib Chowdhary, MBBS, PhD,^c Mark S. Spence, MD,^d Ganesh Manoharan, MD,^d Colum G. Owens, MD,^d Paul F. Brennan, MB BCh BAO,^d David Roberts, MD,^e Ranjit More, MB ChB,^e Andrew Wiper, MB ChB,^e Hesham K. Abdelaziz, MD, PhD^{e,f} Darren Mylotte, MD,^g Antoinette Neylon, MB BCh,^g Niamh Martin,^g Federico Mercanti, MD,^g Stephen Dorman, BM BCh (Hons),^h Vasileios Panoulas, MD, PhDⁱ Miles Dalby, MD,ⁱ Mavin N. Kashyap, MBBS,ⁱ Tito Kabir, MBBS, PhD,ⁱ Jan Kovac, MD,^j Kosmas Kontoprias, MD,^j Iqbal Malik, MBBCh, PhD,^k Ghada Mikhail, MD,^k Sayan Sen, MRCP, PhD,^k Neil Ruparelia, MBBS, DPhil,^k Ozan M. Demir, MBBS,^k Angela Frame, MSc,^k Neal Uren, MD,^l Richard Anderson, MD,^m Thirumaran Rajathurai, MD,ⁿ Luke Tapp, MBBS,ⁿ Lauren Deegan, BSc,ⁿ Ever Grech, MD,^o Ian Hall, MD,^o Melanie Neville, BSc (Hons),^o Rajiv Rampat, MD,^p David Hildick-Smith, MD,^p Michael Mullen, MD,^q Simon Kennon, MD,^q Pavan Chandrala, MBBS,^q Sagar Doshi, MD,^r Stephen J. Brecker, MD^a

Authors' Affiliations: From the ^aCardiology Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, London, United Kingdom; ^bLeeds General Infirmary, Leeds, United Kingdom; ^cManchester University NHS Foundation Trust, Manchester, United Kingdom; ^dRoyal Victoria Hospital, Belfast, United Kingdom; ^eBlackpool Victoria Hospital, Blackpool, United Kingdom; ^fCardiovascular Department, Ain Shams University, Cairo, Egypt; ^gUniversity Hospital Galway, Galway, Ireland; ^hBristol Heart Institute, Bristol, United Kingdom; ⁱHarefield Hospital, London, United Kingdom; ^jBiomedical Research Unit, University of Leicester, Leicester, United Kingdom; ^kHammersmith Hospital, London, United Kingdom; ^lRoyal Infirmary of Edinburgh, Edinburgh, United Kingdom; ^mUniversity Hospital of Wales, Cardiff, United Kingdom; ⁿUniversity Hospital, Coventry, United Kingdom; ^oNorthern General Hospital, Sheffield, United Kingdom; ^pRoyal Sussex County Hospital, Brighton, United Kingdom; ^qSt. Bartholomew's Hospital, London, United Kingdom; and the ^rQueen Elizabeth Hospital, Birmingham, United Kingdom.

Total Word Count: 3301 words.

Indexing Words:

Transcatheter Valve Implantation

Aortic Valve Disease

Aortic Valve Disease, Percutaneous Intervention

Address for Correspondence:

Dr. Cameron Dowling

Department of Cardiology

St. George's Hospital

Blackshaw Rd, London SW17 0QT

United Kingdom

Telephone: +44-(0)20-8725-3556

Fax: +44-(0)20-8725-0211

Email: Cameron.Dowling@stgeorges.nhs.uk

Abstract

Objectives

The UK & Ireland Implanters' registry is a multicentre registry which reports on real-world experience with novel transcatheter heart valves.

Background

The 34 mm Evolut R transcatheter aortic valve is a self-expanding and fully recapturable transcatheter aortic valve, designed to treat patients with a large aortic annulus.

Methods

Between January 2017 and April 2018, clinical, procedural and 30-day outcome data were prospectively collected from all patients receiving the 34 mm Evolut R valve across 17 participating centres in the United Kingdom and Ireland. The primary efficacy outcome was the Valve Academic Research Consortium-2 (VARC-2)-defined endpoint of device success. The primary safety outcome was the VARC-2-defined composite endpoint of early safety at 30 days.

Results

A total of 217 patients underwent attempted implant. Mean age was 79.5 ± 8.8 years and Society of Thoracic Surgeons Predicted Risk of Mortality Score $5.2 \pm 3.4\%$. Iliofemoral access was used in 91.2% of patients. Device success was 79.7%. Mean gradient was 7.0 ± 4.6 mm Hg and effective orifice area 2.0 ± 0.6 cm². Paravalvular regurgitation was more than mild in 7.2%. A new permanent pacemaker was implanted in 15.7%. Early safety was demonstrated in 91.2%. At 30 days, all-cause mortality was 3.2%, stroke 3.7% and major vascular complication 2.3%.

Conclusions

Real-world experience of the 34 mm Evolut R transcatheter aortic valve demonstrated acceptable procedural success, safety, valve function and incidence of new permanent pacemaker implantation.

Introduction

Transcatheter aortic valve replacement (TAVR) with a self-expanding prosthesis is a well-established therapy for the treatment of patients with severe aortic stenosis who are at extreme, high and intermediate-risk for surgery (1-3). Until recently, patients with an aortic annulus diameter >29 mm were not treatable with a self-expanding prosthesis, and further, patients with an aortic annulus diameter >29.5 mm were not treatable with any commercially available transcatheter aortic valve (4).

The 34 mm Evolut R transcatheter aortic valve (Medtronic, Minneapolis, Minnesota) is a second-generation transcatheter aortic valve which is designed to treat patients with an aortic annulus diameter between 26 and 30 mm. The key design changes from the first-generation CoreValve have been described previously (5). In brief, the nitinol frame has been modified so that the inflow portion is wider and more cylindrical, providing more consistent radial force. The outflow portion is shorter and narrower, improving anatomical fit in highly angulated aortas. The porcine pericardial inflow skirt has been extended, with the aim of reducing paravalvular regurgitation. The valve is delivered using the 16-F equivalent EnVeo R delivery catheter system, which reduces the minimum transarterial access vessel diameter to 5.5 mm. The system may also be delivered through a 20-F introducer sheath. The nitinol delivery catheter capsule allows for resheathing and full recapture during deployment.

The UK & Ireland Implanters' registry is a multicentre registry which reports on real-world experience with novel transcatheter heart valves. Our group has previously reported on the procedural, clinical and 30-day outcome data of the 23, 26 and 29 mm Evolut R transcatheter aortic valves, which reflected our early experience with the Evolut R system between December 2013 and May 2016 (6). Here we describe our initial experience with the 34 mm Evolut R valve.

Materials and Methods

Between January 2017 and April 2018, clinical, procedural and 30-day outcome data were prospectively collected on all patients receiving the 34 mm Evolut R valve across 17 participating centres in the United Kingdom and Ireland.

The primary efficacy outcome was the Valve Academic Research Consortium-2 (VARC-2)-defined composite endpoint of device success at 30 days (7). This composite endpoint requires the presence of all of the following (1) absence of procedural (30-day and index hospitalization) mortality, (2) correct positioning of a single prosthetic heart valve into the proper anatomical location, (3) no patient-prosthesis mismatch (body surface area indexed effective orifice area of $>0.85 \text{ cm}^2/\text{m}^2$ or $>0.70 \text{ cm}^2/\text{m}^2$ for patients with a body mass index $\geq 30 \text{ kg}/\text{m}^2$), (4) a mean aortic valve gradient $<20 \text{ mm Hg}$ or peak velocity $<3 \text{ m/s}$, and (5) no moderate or severe prosthetic valve regurgitation.

The primary safety outcome was the VARC-2-defined composite endpoint of early safety at 30 days. Components of this endpoint are (1) all-cause mortality, (2) all stroke, (3) life-threatening bleeding, (4) acute kidney injury stage 2 or 3 (including renal replacement therapy), (5) coronary artery obstruction requiring intervention, (6) major vascular complication, and (7) valve-related dysfunction requiring a repeat procedure (balloon aortic valvuloplasty, TAVR or surgical aortic valve replacement).

Secondary outcomes included 30-day valve hemodynamics, paravalvular regurgitation severity, new permanent pacemaker implantation and symptom status.

Statistical analysis

1
2
3 Statistical analysis was performed with SPSS version 24.0 (IBM Corporation, Armonk, New
4
5 York). Categorical variables are summarized as numbers and percentages. Continuous
6
7 variables are presented as mean \pm SD or median (interquartile range). Comparisons between
8
9 continuous and categorical variables were evaluated with Student's t-test and Fisher's exact
10
11 test, respectively, with a two-sided p value <0.05 considered statistically significant.
12
13
14

15 16 **Results**

17 18 19 Patient Characteristics

20
21 A total of 217 patients underwent implant. Baseline characteristics are listed in
22
23 Table I. Patients were elderly (age 79.5 ± 8.8 years), largely male (95.4%) and at
24
25 intermediate-risk for surgery (Society of Thoracic Surgeons Predicted Risk of Mortality $5.2 \pm$
26
27 3.4%). There was a high prevalence of frailty (18.9%). Although the majority of patients
28
29 were treated for native tricuspid aortic stenosis, there was a relatively high prevalence of
30
31 complex anatomy, including pure native aortic regurgitation (4 patients), failed bioprosthetic
32
33 aortic valve replacement (1 patient), failed aortic root homograft (2 patients) and bicuspid
34
35 aortic stenosis (12 patients). The mean aortic annulus diameter was 27.1 ± 1.7 mm (mean
36
37 aortic annulus perimeter 86.4 ± 4.9 mm), the largest aortic annulus diameter was 31 mm
38
39 (perimeter 103.0 mm) and 13 patients (6.0%) had an aortic annulus larger than the
40
41 manufacturer recommendations.
42
43
44
45
46
47

48 49 Procedural Characteristics

50
51 Procedural characteristics are listed in Table II. Cases were mostly performed under local
52
53 anaesthesia or conscious sedation (59.0%). Iliofemoral access predominated (91.2%) with
54
55 subclavian access being the most common alternative access approach (7.4%). For
56
57
58
59
60

1
2
3 iliofemoral cases, the valve was typically delivered using the 16-F equivalent EnVeo R
4 delivery catheter, without the need for a separate introducer sheath (89.9%). Pre-implant
5 balloon valvuloplasty was performed in 52.1% of cases. The resheathing or recapture
6 functionality was used in 27.2% of cases. Final implant depth was 5.6 ± 3.1 mm. Post-
7 implant balloon valvuloplasty was performed in 21.7% of cases. Median length of stay post-
8 procedure was 3 days (interquartile range 2 to 5 days).
9
10
11
12
13
14
15

16 Device Success

17
18 Overall device success was 79.7% (Table III). There were two cases where a transcatheter
19 aortic valve could not be deployed. One iliofemoral case had to be terminated due to an
20 inability to advance the delivery catheter through the iliac vessels. One valve could not be
21 deployed in a stable position in an aortic root homograft and was fully recaptured.
22
23
24
25
26
27

28
29 There were four cases which required a second prosthesis. In the first case the valve
30 become invaginated after resheathing and would not re-expand. It was fully recaptured and a
31 second 34 mm Evolut R prosthesis was placed without sequelae. In the second case (aortic
32 annulus diameter 30.6 mm) the valve migrated on release to a depth of 15 mm and there was
33 severe paravalvular regurgitation. While attempting to snare the prosthesis back into the
34 aortic annulus, the valve embolized into the ascending aorta and a second 34 mm Evolut R
35 valve was then deployed without sequelae. In the third case (aortic annulus diameter 25.1
36 mm), the valve embolized into the ascending aorta upon device release and a second 34 mm
37 Evolut R valve was deployed without complication. In the fourth case (aortic annulus
38 diameter 28.5 mm) the valve migrated on release to a depth of 20 mm, which was associated
39 with severe paravalvular regurgitation. Two additional 34 mm Evolut R prostheses were
40 deployed, reducing paravalvular regurgitation to moderate.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 There were an additional three cases of valve migration, all of which occurred
4 immediately after final release (Table IV). There were no cases of coronary occlusion,
5 annular rupture, ventricular perforation or need for sternotomy.
6
7
8
9

10 11 Early Safety

12
13 Early safety was demonstrated in 91.2%. (Table III). There were no immediate procedural
14 mortalities, but seven patients (3.2%) died within 30 days of the procedure. Two patients died
15 from bleeding (one from femoral access site vascular injury, one from complications of
16 sternotomy for direct aortic approach). One patient died from spontaneous myocardial
17 infarction four days post-procedure. There were four non-cardiac deaths. There were eight
18 strokes (3.7%) and five major vascular complications (2.3%).
19
20
21
22
23
24
25

26
27 Re-intervention was required in three patients. The first patient developed moderate
28 paravalvular regurgitation, which was treated 14 days post procedure with a second 34 mm
29 Evolut R valve, reducing severity to trivial. The second patient developed moderate
30 paravalvular regurgitation, which was treated 63 days post procedure with balloon
31 valvuloplasty using a 24 mm TRUE dilatation balloon (BARD Peripheral Vascular, Tempe,
32 Arizona), reducing severity to mild. The third patient developed severe paravalvular
33 regurgitation and was treated 103 days post procedure with an AMPLATZER Vascular Plug
34 4 (Abbott Vascular, Santa Clara, California), reducing severity to moderate.
35
36
37
38
39
40
41
42
43
44
45

46 Secondary Outcomes

47
48 Echocardiographic follow-up was available for 207 patients. At 30 days, mean gradient was
49 7.0 ± 4.6 mm Hg and effective orifice area 2.0 ± 0.6 cm² (Figure 1). More than mild
50 paravalvular regurgitation was present in 15 patients (7.2%) (Figure 2).
51
52
53
54
55
56
57
58
59
60

1
2
3 A new permanent pacemaker was implanted in 15.7% of patients without a
4
5 pacemaker at baseline.

6
7 Follow-up symptom status information was available for 108 patients. Symptom relief
8
9 was observed, with 91 patients (84.3%) improving by at least one New York Heart
10
11 Association functional class (Figure 3).
12
13

14 15 16 Outcomes in Bicuspid Patients

17
18 Twelves patients were treated for bicuspid aortic stenosis. One patient development moderate
19
20 paravalvular regurgitation (8.3%) and two patients required permanent pacemaker
21
22 implantation (22.9% of patients without a pacemaker at baseline). Early safety was
23
24 demonstrated in all patients.
25
26

27 28 29 Outcomes in Pure Aortic Regurgitation

30
31 Four inoperable patients were treated for pure aortic regurgitation. Device annular sizing ratio
32
33 was $28.3 \pm 2.6\%$. There were no cases of moderate paravalvular regurgitation and two
34
35 patients (50.0%) required permanent pacemaker implantation. There was one case of valve
36
37 migration as has previously been discussed. Early safety was demonstrated in all patients.
38
39

40 41 42 Risk Factors for Complications

43
44 Pre-existing right bundle branch block was associated with a significantly higher risk of new
45
46 permanent pacemaker (62.5% vs. 13.5%, $p = 0.003$). Implant depth was significantly lower in
47
48 patient requiring a new permanent pacemaker (8.9 ± 3.7 vs. 4.8 ± 2.2 mm, $p < 0.001$) and
49
50 further, a deep implant (>5 mm) was associated with a significantly higher risk of new
51
52 permanent pacemaker (35.1 vs. 10.6%, $p < 0.001$).
53
54
55
56
57
58
59

1
2
3 Device annular sizing ratio was significantly lower in patients who developed more
4 than mild paravalvular regurgitation (19.8 ± 7.3 vs. $26.0 \pm 7.9\%$, $p = 0.04$).
5
6
7

8 9 Comparison to the 23, 26 and 29 mm Valve Sizes

10
11 When compared to our previous experience of the smaller valve sizes, patients in the 34 mm
12 registry had broadly similar baseline characteristics, but with some important differences
13 (Supplementary Table I). The 34 mm group had a higher proportion of men and a higher
14 prevalence of pre-existing permanent pacemaker or defibrillator. Fewer valve-in-valve
15 procedures were undertaken with the 34 mm valve size.
16
17
18
19
20
21

22 Procedural differences were noted between the two cohorts (Supplementary Table II).
23 The 34 mm valve procedures, which were undertaken in a more contemporary time period,
24 were more frequently performed under local anesthesia or conscious sedation. The larger
25 valve size saw more frequent usage of the EnVeO R delivery catheter without an introducer
26 sheath. Both pre-implant balloon valvuloplasty and use of the EnVeO R delivery system's
27 resheathing and recapture function were more common with the 34 mm valve size.
28
29
30
31
32
33
34

35 Device success, early safety, more than mild paravalvular regurgitation and new
36 permanent pacemaker implantation were all similar between the two cohorts (Supplementary
37 Table III). Mean aortic valve gradient was lower (7.0 ± 4.6 vs. 8.3 ± 6.0 mm Hg, $p = 0.02$)
38 and effective orifice area was larger (2.0 ± 0.6 vs. 1.7 ± 0.5 cm², $p < 0.001$) with the 34 mm
39 valve size.
40
41
42
43
44
45
46
47

48 **Discussion**

49
50
51
52 We describe here the clinical, procedural and 30-day outcome data of a large cohort of
53 consecutive, real-world patients treated with the 34 mm Evolut R transcatheter aortic valve.
54
55
56
57

1
2
3 Procedural indications were broad, and we demonstrated successful implantations in
4 bioprosthetic surgical valves, aortic root homografts, pure native aortic regurgitation and
5 bicuspid aortic valve morphology.
6
7

8
9 Valve implantation demonstrated a favourable safety profile (all-cause mortality
10 3.2%, stroke 3.7%, life-threatening bleeding 0.9% and major vascular complication 2.3%).
11

12
13 Device success (79.7%) was similar to our experience with the smaller valve sizes
14 (72.3%) and outcomes reported in the Evolut R CE Mark clinical trial (78.6%) (8). Patient-
15 prosthesis mismatch (7.8%) was the largest driver for an unsuccessful procedure, the
16 incidence of which was lower than our experience with the smaller valve sizes (16.3%) and
17 outcomes reported in the Evolut R CE Mark (16.4%) and Evolut R U.S. (26.8%) clinical
18 studies (9).
19
20
21
22
23
24
25

26
27 Valve hemodynamics were excellent with a low mean aortic valve gradient (7.0 ± 4.6
28 mm Hg) and large effective orifice area ($2.0 \pm 0.6 \text{ cm}^2$). Only three patients had a mean aortic
29 valve gradient ≥ 20 mmHg or peak velocity ≥ 3 m/sec.
30
31

32
33 Incidence of more than mild paravalvular regurgitation at 30-days (7.2%) was similar
34 to our experience with the smaller valve sizes (7.8%) and outcomes reported in both the
35 Evolut R CE Mark (6.7%) and Evolut R U.S. (5.3%) clinical studies.(8,9) These findings
36 represent a definite improvement on the outcomes seen with the first-generation CoreValve in
37 the ADVANCE clinical study (15.0%) (10). However, incidence of more than mild
38 paravalvular regurgitation was not as low as has been recently reported in the Evolut R
39 FORWARD clinical study (1.9%), Evolut R 34 mm U.S. clinical study (1.7%), Evolut PRO
40 U.S. clinical study (0.0%) and other 34 mm Evolut R registry data (0.0-5.0%) (11-16). The
41 average implant depth in our study (5.6 ± 3.1 mm) was outside the manufacturer
42 recommendations (3-5 mm), which may explain the higher incidence of more than mild
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 paravalvular regurgitation that we have reported. A 34 mm Evolut PRO valve is currently in
4
5 development, which should reduce this complication.

6
7 Incidence of new permanent pacemaker insertion (15.7%) was similar to our
8
9 experience of the smaller Evolut R prosthesis sizes. However, pre-existing permanent
10
11 pacemaker was more common in patients treated with the 34 mm prosthesis, perhaps
12
13 reflective of an increased tendency for operators to implant prophylactic pacemakers.

14
15 The resheating and recapture ability was frequently used to optimise positioning
16
17 (27.2%) and in two cases was employed to completely remove the transcatheter aortic valve
18
19 from the patient. Usage of these features was more common than with our previous
20
21 experience of the smaller valve sizes, which probably reflects greater operator experience
22
23 using this technology, but may also be indicative of the difficulties in placing transcatheter
24
25 aortic valves in large anatomy, due to an increased prevalence of excessive aortic root
26
27 angulation.

28
29
30 The 16-F equivalent EnVeo R delivery catheter system is larger than the 14-F
31
32 equivalent system used for the 23 to 29 mm Evolut R valves. However, as iliofemoral vessels
33
34 were larger in this cohort, iliofemoral access rates were similar and major vascular
35
36 complications remained low (2.3%). More 34 mm procedures were performed without an
37
38 introducer sheath, likely reflecting greater operator familiarity using the in-line sheath feature
39
40 of the EnVeo R delivery system.

41
42
43 Valve embolization occurred in 2 patients, both whom had aortic annulus dimensions
44
45 outside the manufacturer recommended sizing algorithm. A second 34 mm Evolut R
46
47 prosthesis was successfully implanted in both cases.

48
49
50 Pre-existing right bundle branch block and a low implant depth are both well-
51
52 established risk factor for new permanent pacemaker implantation after TAVR (17). We
53
54 confirmed that these clinical and procedural characteristics were both associated with new
55
56

1
2
3 permanent pacemaker implantation after TAVR with the 34mm Evolut R valve. Device
4
5 annular sizing ratio was associated with the development of more than mild paravalvular
6
7 regurgitation, as has previously been described (9).
8

9
10 The incidence of moderate paravalvular regurgitation reported in this study (7.2%)
11
12 was similar to a recent series of large annuli patients treated with the SAPIEN 3 valve (6.9%)
13
14 (Edwards Lifesciences, Irvine, California), but incidence of permanent pacemaker was higher
15
16 with the the self-expanding prosthesis (15.7% vs 6.3%) (18).
17

18 19 20 Limitations

21
22
23
24 This study should be interpreted within the inherent constraints of a registry. All clinical
25
26 outcomes were site reported. There was no usage of a core laboratory for assessing
27
28 echocardiographic outcomes. Echocardiographic and clinical follow-up information was not
29
30 available for all patients. Further work is needed to establish long-term prosthesis durability.
31

32
33 However, this study has considerable strengths, specifically the prospective,
34
35 consecutive data collection on real-world, unselected patients, that reflect day-to-day clinical
36
37 practice.
38

39 40 41 **Conclusion**

42
43
44
45
46 In this study we have described our initial experience of a large, self-expanding and fully
47
48 recapturable transcatheter aortic valve. Procedural success, safety, valve function and
49
50 incidence of new permanent pacemaker implantation were all acceptable and similar to
51
52 previous studies of the Evolut R prosthesis.
53
54
55
56
57

References

1. Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D, Hermiller J, Jr., Hughes GC, Harrison JK, Coselli J and others. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. *J Am Coll Cardiol* 2014;63(19):1972-81.
2. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J, Jr., Kleiman NS and others. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014;370(19):1790-8.
3. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H and others. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med* 2017;376(14):1321-1331.
4. van Gils L, Tchetché D, Latib A, Sgroi C, Manoharan G, Mollmann H, Van Mieghem NM. TAVI with current CE-marked devices: strategies for optimal sizing and valve delivery. *EuroIntervention* 2016;12(Y):Y22-7.
5. Sinning JM, Werner N, Nickenig G, Grube E. Medtronic CoreValve Evolut R with EnVeo R. *EuroIntervention* 2013;9 Suppl:S95-6.
6. Kalra SS, Firoozi S, Yeh J, Blackman DJ, Rashid S, Davies S, Moat N, Dalby M, Kabir T, Khogali SS and others. Initial Experience of a Second-Generation Self-Expanding Transcatheter Aortic Valve: The UK & Ireland Evolut R Implanters' Registry. *JACC Cardiovasc Interv* 2017;10(3):276-282.
7. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA and others. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). *Eur J Cardiothorac Surg* 2012;42(5):S45-60.

- 1
2
3 8. Manoharan G, Walton AS, Brecker SJ, Pasupati S, Blackman DJ, Qiao H, Meredith
4 IT. Treatment of Symptomatic Severe Aortic Stenosis With a Novel Resheathable Supra-
5 Annular Self-Expanding Transcatheter Aortic Valve System. *JACC Cardiovasc Interv*
6 2015;8(10):1359-67.
7
8
- 9
10
11 9. Popma JJ, Reardon MJ, Khabbaz K, Harrison JK, Hughes GC, Kodali S, George I,
12 Deeb GM, Chetcuti S, Kipperman R and others. Early Clinical Outcomes After Transcatheter
13 Aortic Valve Replacement Using a Novel Self-Expanding Bioprosthesis in Patients With
14 Severe Aortic Stenosis Who Are Suboptimal for Surgery: Results of the Evolut R U.S. Study.
15 *JACC Cardiovasc Interv* 2017;10(3):268-275.
16
17
- 18 10. Linke A, Wenaweser P, Gerckens U, Tamburino C, Bosmans J, Bleiziffer S,
19 Blackman D, Schafer U, Muller R, Sievert H and others. Treatment of aortic stenosis with a
20 self-expanding transcatheter valve: the International Multi-centre ADVANCE Study. *Eur*
21 *Heart J* 2014;35(38):2672-84.
22
23
- 24 11. Grube E, Van Mieghem NM, Bleiziffer S, Modine T, Bosmans J, Manoharan G,
25 Linke A, Scholtz W, Tchetché D, Finkelstein A and others. Clinical Outcomes With a
26 Repositionable Self-Expanding Transcatheter Aortic Valve Prosthesis: The International
27 FORWARD Study. *J Am Coll Cardiol* 2017;70(7):845-853.
28
29
- 30 12. Bajwa T, O'Hair DP, Williams M, Mumtaz M, Gada H, Chetcuti S, Deeb GM, Popma
31 JJ. TCT-357 Transcatheter Aortic Valve Replacement with a 34-mm Repositionable Self-
32 Expanding Bioprosthesis. *Journal of the American College of Cardiology* 2017;70(18
33 Supplement):B147.
34
35
- 36 13. Forrest JK, Mangi AA, Popma JJ, Khabbaz K, Reardon MJ, Kleiman NS, Yakubov
37 SJ, Watson D, Kodali S, George I and others. Early Outcomes With the Evolut PRO
38 Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap. *JACC*
39 *Cardiovasc Interv* 2018;11(2):160-168.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 14. Harnath A, Gomes B, Herwig V, Gatto F, Watremez S, Katus HA, Bekeredjian R.
4 First experience with the 34 mm self-expanding Evolut R in a multicentre registry.
5 EuroIntervention 2018;14(3):e298-e300.
6
7
8
9 15. Kuhn C, Frerker C, Meyer A-K, Kurz T, Schäfer U, Deuschl F, Abdel-Wahab M,
10 Schewel D, Elghalban A, Kuck K-H and others. Transcatheter aortic valve implantation with
11 the 34 mm self-expanding CoreValve Evolut R: initial experience in 101 patients from a
12 multicentre registry. EuroIntervention 2018;14(3):e301-e305.
13
14
15
16
17 16. D'Ancona G, Dissmann M, Heinze H, Zohlhofer-Momm D, Ince H, Kische S.
18 Transcatheter aortic valve replacement with the 34mm Medtronic Evolut valve : Early results
19 of single institution experience. Neth Heart J 2018;26(7-8):401-408.
20
21
22
23
24 17. Popma JJ. Predictors of pacemaker implantation with a self-expanding repositionable
25 transcatheter aortic valve. Presented at EuroPCR 2016, 20 May, 2016. Paris, France.
26
27
28
29 18. Tang GHL, Zaid S, George I, Khaliq OK, Abramowitz Y, Maeno Y, Makkar RR,
30 Jilaihawi H, Kamioka N, Thourani VH and others. Impact of Aortic Root Anatomy and
31 Geometry on Paravalvular Leak in Transcatheter Aortic Valve Replacement With Extremely
32 Large Annuli Using the Edwards SAPIEN 3 Valve. JACC Cardiovasc Interv
33 2018;11(14):1377-1387.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure Titles and Descriptive Legends**
4
5

6
7 Figure 1. Aortic Valve Hemodynamics.
8

9 Error bars represent 1 SD.
10
11

12
13 Figure 2. Aortic/Paravalvular Regurgitation.
14
15

16
17 Figure 3. Symptom Status.
18

19 NYHA = New York Heart Association.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Aortic Valve Hemodynamics. Error bars represent 1 SD.

220x181mm (240 x 240 DPI)




Figure 2. Aortic/Paravalvular Regurgitation.

224x181mm (240 x 240 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Symptom Status. NYHA = New York Heart Association.

204x181mm (240 x 240 DPI)



Table I. Baseline Clinical Characteristics

	N = 217
Age, years	79.5 ± 8.8
Body surface area, m ²	2.0 ± 0.2
Male	207 (95.4)
STS PROM Score	5.2 ± 3.4
NYHA Functional Class III/IV	174 (80.2)
Diabetes	49 (22.6)
Serum Creatinine > 2 mg/dL	11 (5.1)
Chronic lung disease/COPD	73 (33.6)
Peripheral vascular disease	44 (20.3)
Cerebrovascular disease	31 (14.3)
LVEF <50%	72 (33.2)
Previous CABG	41 (18.9)
Previous SAVR	3 (1.4)
Previous PCI	53 (24.4)*
Previous MI	56 (25.8)
Atrial fibrillation/atrial flutter	61 (28.1)
Other comorbidities and medical history	
Porcelain aorta	18 (8.3)
Frailty†	41 (18.9)
Cirrhosis of the liver	1 (0.5)
Pre-existing permanent pacemaker or defibrillator	39 (18.0)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CABG = coronary artery bypass grafting; LVEF = left ventricular ejection fraction, MI = myocardial infarction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention, SAVR = surgical aortic valve replacement, STS PROM = Society of Thoracic Surgery Predictor of Mortality

*Including 16 interventions which were performed as staged revascularization for TAVR

†Canadian Study of Health and Aging Clinical Frailty Scale ≥ 5 (mildly frail)

For Review Only

Table II. Procedural Characteristics

	N = 217
Elective procedure	178 (82.0)
Local anaesthesia or conscious sedation	128 (59.0)
Delivery approach	
Iliofemoral	198 (91.2)
Subclavian	16 (7.4)
Direct aortic	3 (1.4)
Cerebral protection	15 (6.9)
Minimum iliofemoral diameter on TAVR access side (mm)	7.5 ± 1.6
Delivery sheath for iliofemoral cases	
EnVeo R delivery catheter only	178 (89.9)
EnVeo R delivery catheter with an introducer sheath	20 (10.1)
Pre-implant balloon valvuloplasty	113 (52.1)
Resheathing performed	49 (22.6)
Recapture performed	26 (12.0)
Resheathing or recapture performed	59 (27.2)
Final implant depth (mm)*	5.6 ± 3.1
Post-implant balloon valvuloplasty†	47 (21.7)

*Average of non- and left-coronary sinus

†Performed during the same procedure

Table III. Procedural Outcomes

	N = 217
Device success	173 (79.7)
Absence of procedural mortality	210 (96.8)
Positioning of a single prosthesis into the proper anatomical location	211 (97.2)
Absence of patient-prosthesis mismatch	200 (92.2)
Mean aortic valve gradient <20 mm Hg or peak velocity <3 m/s	214 (98.6)
Absence of moderate or severe regurgitation	202 (93.1)
30-day early safety	19 (8.8)
All-cause mortality	7 (3.2)
Stroke	8 (3.7)
Life threatening bleeding	2 (0.9)
Acute kidney injury (Stage 2 or 3)	2 (0.9)
Coronary obstruction requiring intervention	0 (0.0)
Major vascular complication	5 (2.3)
Valve-related dysfunction requiring repeat procedure	1 (0.5)*
30-day new permanent pacemaker implantation†	28 (15.7)

*Re-intervention was performed in 2 patients >30 days post TAVR

†Excluding patients with a pacemaker at baseline

Table IV. Valve Migration.

Case	Aortic annulus diameter (mm)	Final implant depth (mm)	Paravalvular Regurgitation
1*	27.1	16	Mild
2	27.3	13	Moderate
3	28.5	16	Mild

*Case performed for pure aortic regurgitation

For Review Only

Supplementary Table I. Baseline Clinical Characteristics in the 23/26/29 and 34 mm Evolut R Implanters' Registries.

	23/26/29 mm N = 264	34 mm N = 217	p Value
Age, years	81.1 ± 7.8	79.5 ± 8.8	0.07
Body surface area, m ²	1.8 ± 0.2	2.0 ± 0.2	<0.001
Male	110 (41.7)	207 (95.4)	<0.001
STS PROM Score	6.0 ± 5.6	5.2 ± 3.4	0.52
NYHA Functional Class III/IV	229 (86.7)	174 (80.2)	0.06
Diabetes	66 (25.0)	49 (22.6)	0.59
Serum Creatinine > 2 mg/dL	11 (4.2)	11 (5.1)	0.67
Chronic lung disease/COPD	71 (26.9)	73 (33.6)	0.11
Peripheral vascular disease	63 (23.9)	44 (20.3)	0.38
Cerebrovascular disease	31 (11.7)	31 (14.3)	0.42
Previous SAVR	28 (10.6)	3 (1.4)	<0.001
Previous PCI	72 (27.3)	53 (24.4)*	0.53
Atrial fibrillation/atrial flutter	58 (22.0)	61 (28.1)	0.14
Other comorbidities and medical history			
Cirrhosis of the liver	4 (1.5)	1 (0.5)	0.38
Pre-existing permanent pacemaker or defibrillator	19 (7.2)	39 (18.0)	<0.001

CABG = coronary artery bypass grafting; MI = myocardial infarction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention, SAVR = surgical aortic valve replacement, STS PROM = Society of Thoracic Surgery Predictor of Mortality

*Including 16 interventions which were performed as staged revascularization for TAVR

†Canadian Study of Health and Aging Clinical Frailty Scale ≥ 5 (mildly frail)

For Review Only

Supplementary Table II. Procedural Characteristics in the 23/26/29 and 34 mm Evolut R Implanters' Registries.

	23/26/29 mm N = 264	34 mm N = 217	p Value
Annual centre TAVR volume (cases)	86 ± 52	119 ± 78	0.003
Elective procedure	218 (82.6)	178 (82.0)	0.90
Local anaesthesia or conscious sedation	105 (39.8)	128 (59.0)	<0.001
Delivery approach			
Iliofemoral	247 (93.6)	198 (91.2)	0.39
Subclavian	14 (5.3)	16 (7.4)	0.45
Direct aortic	3 (1.1)	3 (1.4)	>0.99
Minimum iliofemoral diameter on TAVR access side (mm)	7.0 ± 1.4	7.5 ± 1.6	0.003
Delivery sheath for iliofemoral cases			
EnVeo R delivery catheter only	169 (68.4)	178 (89.9)	<0.001
EnVeo R delivery catheter with an introducer sheath	78 (31.6)	20 (10.1)	<0.001
Pre-implant balloon valvuloplasty	73 (27.7)	113 (52.1)	<0.001
Resheathing performed	46 (17.4)	49 (22.6)	0.17
Recapture performed	37 (14.0)	26 (12.0)	0.59
Resheathing or recapture performed	50 (18.9)	59 (27.2)	0.04
Post-implant balloon valvuloplasty*	60 (22.7)	47 (21.7)	0.83

*Performed during the same procedure

Supplementary Table III. Procedural Outcomes in the 23/26/29 and 34 mm Evolut R Implanters' Registries.

	23/26/29 mm N = 264	34 mm N = 217	p Value
Device success	191 (72.3)	173 (79.7)	0.07
Absence of procedural mortality	258 (97.7)	210 (96.8)	0.58
Positioning of a single prosthesis into the proper anatomical location	255 (96.6)	211 (97.2)	0.80
Absence of patient-prosthesis mismatch	221 (83.7)	200 (92.2)	0.006
Mean aortic valve gradient <20 mm Hg or peak velocity <3 m/s	253 (95.8)	214 (98.6)	0.10
Absence of moderate or severe regurgitation	246 (93.2)	202 (93.1)	>0.99
30-day early safety	29 (11.0)	19 (8.8)	0.45
All-cause mortality	6 (2.3)	7 (3.2)	0.58
Stroke	10 (3.8)	8 (3.7)	>0.99
Life threatening bleeding	4 (1.5)	2 (0.9)	0.69
Acute kidney injury (Stage 2 or 3)	2 (0.8)	2 (0.9)	>0.99
Coronary obstruction requiring intervention	2 (0.8)	0 (0.0)	0.50
Major vascular complication	14 (5.3)	5 (2.3)	0.10
Valve-related dysfunction requiring repeat procedure	0 (0.0)	1 (0.5)*	0.45
30-day new permanent pacemaker implantation†	36 (14.7)	28 (15.7)	0.78

*Re-intervention was performed in 2 patients >30 days post TAVR

†Excluding patients with a pacemaker at baseline